SARS-COV-2 infection in patients with hereditary thrombophilia: Is there a worsening in COVID-19 symptoms?

Abstract

Patients with COVID-19 who progressed to a more advanced stage of the disease were observed to develop coagulation disorders. Mutations in genes encoding clotting factors, such as Prothrombin Factor II, Leiden Factor V and MTHFR are associated with the development of thromboembolism. The aim of this study was to determine the prevalence of genetic variants present in these genes in patients with COVID-19, and to associate their presence with disease severity and D-dimer values. 405 patients with different manifestations of COVID-19 were genotyped by qPCR; genotypes were associated with disease severity and D-dimer values. A slightly prevalence of the FVL mutated allele in the group with positive diagnosis was found; also, higher levels of D-dimer in patients who required treatment in intensive care were observed. Individuals with hereditary thrombophilia are at greater risk of developing a thrombolytic event after infection (long-term COVID). Our data show the benefits of performing genetic screening for hereditary thrombophilia in individuals infected with SARS-Cov-2 in order to establish, together with classical laboratory parameters, a risk factor for the development of thrombosis both during the infectious process and for post-COVID and thus avoid a vascular event.